2018
Variable impact of prior cancer history on the survival of lung cancer patients
Monsalve AF, Hoag JR, Resio BJ, Chiu AS, Brown LB, Detterbeck FC, Blasberg JD, Boffa DJ. Variable impact of prior cancer history on the survival of lung cancer patients. Lung Cancer 2018, 127: 130-137. PMID: 30642541, DOI: 10.1016/j.lungcan.2018.11.040.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPrior cancer historyNational Cancer DatabaseCancer historyOverall survivalNSCLC patientsMultivariable Cox proportional hazards regression modelsTreatment approachesCox proportional hazards regression modelProportional hazards regression modelsKaplan-Meier survival curvesNSCLC patient survivalCell lung cancerHazards regression modelsLung cancer patientsPrior cancerPrior malignancyNSCLC survivalPatient survivalCancer patientsLung cancerCancer DatabasePatient's potentialPrior historyPatients
2016
Hospital Volume and Outcomes of Robot-Assisted Lobectomies
Tchouta LN, Park HS, Boffa DJ, Blasberg JD, Detterbeck FC, Kim AW. Hospital Volume and Outcomes of Robot-Assisted Lobectomies. CHEST Journal 2016, 151: 329-339. PMID: 27687847, DOI: 10.1016/j.chest.2016.09.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedCase-Control StudiesCohort StudiesDatabases, FactualFemaleHospital MortalityHospitals, High-VolumeHospitals, Low-VolumeHumansLength of StayLinear ModelsLogistic ModelsLungLung NeoplasmsMaleMiddle AgedMultivariate AnalysisPneumonectomyPostoperative ComplicationsRetrospective StudiesRobotic Surgical ProceduresThoracic Surgery, Video-AssistedTreatment OutcomeConceptsLength of stayLow-volume centersHospital volumeClinical impactHealth care system-related factorsShorter mean LOSUtilization Project National Inpatient Sample databaseVolume/outcome relationshipLong-term clinical impactMean LOSNational Inpatient Sample databaseShorter LOSVideo-assisted thoracoscopic surgeryHospital operative volumeHigh-volume hospitalsIncidence of complicationsHigher hospital volumeThoracoscopic surgery lobectomyAnnual case volumeSystem-related factorsOutcomes of interestLOS outcomesInfectious complicationsInpatient mortalityIndependent predictors
2015
Gender, Age, and Comorbidity Status Predict Improved Survival with Adjuvant Chemotherapy Following Lobectomy for Non-small Cell Lung Cancers Larger than 4 cm
Sandler BJ, Wang Z, Hancock JG, Boffa DJ, Detterbeck FC, Kim AW. Gender, Age, and Comorbidity Status Predict Improved Survival with Adjuvant Chemotherapy Following Lobectomy for Non-small Cell Lung Cancers Larger than 4 cm. Annals Of Surgical Oncology 2015, 23: 638-645. PMID: 26474557, DOI: 10.1245/s10434-015-4902-8.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAge FactorsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChemotherapy, AdjuvantCohort StudiesCombined Modality TherapyComorbidityFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingPneumonectomyPrognosisSex FactorsSurvival RateYoung AdultConceptsNon-small cell lung cancerAdjuvant chemotherapyNational Cancer Data BaseNon-small cell lungCharlson-Deyo scorePretreatment prognostic factorsCell lung cancerCD scoresGroup of womenGroup of menConclusionsAdjuvant chemotherapySurvival benefitT2 tumorsPrognostic factorsDistant metastasisWomen 65Cell lungLung cancerNSCLC tumorsImproved outcomesChemotherapySurgeryPatientsWomenSurvival
2014
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposal for an Evidence-Based Stage Classification System for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors
Detterbeck FC, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL, Frazier AA, Giaccone G, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson AG, Okumura M, Ruffini E, Van Schil P, Committee††† O, Boards‡‡‡ M, Domain§§§ P. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposal for an Evidence-Based Stage Classification System for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. Journal Of Thoracic Oncology 2014, 9: s65-s72. PMID: 25396314, DOI: 10.1097/jto.0000000000000290.Peer-Reviewed Original Research
2012
Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review
Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC. Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review. JAMA 2012, 307: 2418-2429. PMID: 22610500, PMCID: PMC3709596, DOI: 10.1001/jama.2012.5521.Peer-Reviewed Original ResearchConceptsLow-dose computed tomographyLung cancer mortalityLung cancerLDCT screeningCancer deathCancer mortalityEffect of LDCTSystematic reviewNational Lung Screening TrialEvidence-based clinical guidelinesFrequency of followLung cancer deathsLung cancer screeningRisk of deathPotential harmAdvanced diseaseCause mortalityCohort studyMost patientsSecondary outcomesMajor complicationsPrimary outcomeRandomized studyRandomized trialsCT screeningThoroughness of Mediastinal Staging in Stage IIIA Non-small Cell Lung Cancer
Vest MT, Tanoue L, Soulos PR, Kim AW, Detterbeck F, Morgensztern D, Gross CP. Thoroughness of Mediastinal Staging in Stage IIIA Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2012, 7: 188-195. PMID: 22134069, PMCID: PMC3253367, DOI: 10.1097/jto.0b013e318236ecbb.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiopsy, NeedleCarcinoma, Non-Small-Cell LungCohort StudiesComorbidityConfidence IntervalsGuideline AdherenceHumansLung NeoplasmsLymph NodesMediastinoscopyMediastinumMedicareMultivariate AnalysisNeoplasm StagingOdds RatioPositron-Emission TomographySEER ProgramSurvival AnalysisUnited StatesConceptsStage IIIA non-small cell lung cancerIIIA non-small cell lung cancerNon-small cell lung cancerInvasive stagingCell lung cancerMediastinal stagingLung cancerClinical stage IIIA non-small cell lung cancerEnd Results-Medicare databaseStage IIIA NSCLC patientsPositron emission tomography scanningPathologic lymph nodesIIIA NSCLC patientsMultivariable logistic regressionInvasive mediastinal stagingNSCLC patientsOlder patientsPatient characteristicsLymph nodesPatient factorsHistologic confirmationPractice patternsMedicare claimsMedicare beneficiariesPET scanning
2010
High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010, 10: 186. PMID: 20459695, PMCID: PMC2875218, DOI: 10.1186/1471-2407-10-186.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBiomarkers, TumorCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell DifferentiationCohort StudiesConnecticutFemaleGreeceHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm StagingPredictive Value of TestsProportional Hazards ModelsProto-Oncogene Proteins c-bcl-2Reproducibility of ResultsRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUp-RegulationConceptsNon-small cell lung cancer patientsCell lung cancer patientsNon-squamous tumorsLung cancer patientsBcl-2 expressionNSCLC patientsCancer patientsBcl-2Favorable outcomeIndependent cohortSmall cell lung cancer patientsIndependent lower riskNon-squamous histologySubgroup of patientsHigh expressersSquamous cell carcinomaHigh Bcl-2 expressionBcl-2 protein levelsSquamous histologyMedian survivalPrognostic factorsValidation cohortCell carcinomaPathological characteristicsPrognostic stratification
2009
High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma
Anagnostou VK, Bepler G, Syrigos KN, Tanoue L, Gettinger S, Homer RJ, Boffa D, Detterbeck F, Rimm DL. High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma. Clinical Cancer Research 2009, 15: 4157-4164. PMID: 19509151, DOI: 10.1158/1078-0432.ccr-09-0099.Peer-Reviewed Original ResearchConceptsLung cancer patientsMTOR expressionCancer patientsMammalian targetEarly-stage lung adenocarcinomaHigh mTOR expressionIndependent lower riskMedian overall survivalStage IA patientsProtein expressionSubgroup of patientsLung adenocarcinoma patientsStage lung adenocarcinomaMTOR protein expressionRole of mTOROverall survivalPathologic characteristicsPatient survivalValidation cohortAdenocarcinoma groupAdenocarcinoma patientsPrognostic stratificationLung cancerTraining cohortFavorable outcome
2006
Postoperative Radiotherapy for Stage II or III Non–Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results Database
Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative Radiotherapy for Stage II or III Non–Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results Database. Journal Of Clinical Oncology 2006, 24: 2998-3006. PMID: 16769986, DOI: 10.1200/jco.2005.04.6110.Peer-Reviewed Original ResearchConceptsT3-4 tumour stageUse of PORTN2 nodal diseaseEnd Results (SEER) databasePostoperative radiotherapyCell lung cancerLymph nodesNodal diseaseResults databaseTumor stageLung cancerNode stageStage IIHigher American Joint CommitteeAdvanced node stageAmerican Joint CommitteePopulation-based cohortLarger tumor sizeMedian followPerioperative mortalityMale sexTumor sizeSubset analysisCancer stageInclusion criteriaClinical Value of the WHO Classification System of Thymoma
Detterbeck FC. Clinical Value of the WHO Classification System of Thymoma. The Annals Of Thoracic Surgery 2006, 81: 2328-2334. PMID: 16731193, DOI: 10.1016/j.athoracsur.2005.11.067.Peer-Reviewed Original ResearchConceptsWHO systemWorld Health Organization histologic classification systemWHO classification systemIndependent prognostic valueDistinct patient groupsHistologic classification systemClinical management decisionsWHO typePrognostic valuePatient groupClinical valueMultivariate analysisClassification systemThymoma